Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection

Son, Ho Sung; Shin, Yeon Myung; Park, Kwang Kuk; Seo, Kyung Won; Yoon, Ki Hyun; Jang, Hee Kyung; Lee, Sang Ho; Yang, Song I; Kim, Jeong Hoon

doi:10.5230/jgc.2014.14.3.180

Cited by 21 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally agreed that biopsies are preferable to surgical specimens for optimal testing results due to biopsies having more standardized fixation conditions, and this may reflect the differences in HER2‐positivity rates seen in this study. Consistent with previous reports, HER2‐positivity was more frequent with well‐ or moderately differentiated carcinomas (24.0% and 16.0%, respectively), compared with poorly differentiated carcinomas (7.6%).…”

Section: Discussionsupporting

confidence: 92%

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study

Pathmanathan

Geng

et al. 2016

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

Aim Current estimates of the human epidermal growth factor receptor 2 (HER2)‐positivity rate in gastric cancer vary widely in the literature, and there are limited data from countries in Asia. The primary aim of this study was to conduct a clinical audit of laboratories across seven countries in Asia to determine the incidence of HER2‐positive gastric cancer in this region. Methods Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, type and grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory over a 2‐year period. Results HER2 results from 5,301 gastric cancers were submitted by 50 laboratories. The overall HER2‐positivity rate was 9.7% which, after the exclusion of China, increased to 18.1%. The rate between countries ranged from 0% to 23.1%, and from 0% to 50.0% between laboratories. An equivocal HER2 result was recorded in 19.5% of cases. Conclusion Despite the lack of centralized testing to confirm the accuracy of HER2 diagnoses, the incidence of HER2‐positive gastric cancer observed here was comparable to that reported in the literature. Nevertheless, rates were highly variable between countries and laboratories, which suggests a lack of HER2 testing expertise in gastric cancer. Given that the mortality rates for gastric cancer in Eastern Asia are the highest in the world, efforts should focus on improving HER2 testing expertise in the region so that patients receive the appropriate treatment early in their disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study

Pathmanathan

Geng

et al. 2016

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Consistent with previous reports, HER2-positivity was more frequent with well-or moderately differentiated histology (50% and 26%, respectively) (Shan et al, 2013;Son et al, 2014;Rajagopal et at., 2015), compared with poorly differentiated carcinomas (23%). In our study, HER2/neu gene expression is more commonly seen in stage III disease (42% in stage III versus 26% in stage IV), unlike other studies where HER2/neu gene expression is significantly more seen in stage IV of gastric cancer with a larger tumour mass, that can be partly explained by slightly higher numbers of patients with stage III disease (Azarhoosh et al, 2017).…”

Section: Discussionsupporting

confidence: 91%

Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population

Roy

Nyodu

Hazarika

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Gastric cancer is a leading health-care problem worldwide and is the fifth most common cancer in the world, with 952,000 new cases diagnosed in 2012 Worldwide 0.7 million people die of gastric cancer each year (accounts for 8.8% of all cancer-related deaths) [GLOBACON, 2012]. Gastric cancer is the second most common cancer among men and third-most among females in Asia (Rahman et al., 2014) and is the second most common cause of cancer-related deaths in India (Dikshit et al., 2012). A high incidence of gastric cancer has been reported from Southeast Asia, most commonly from Japan, China and South Korea (Ferlay et al., 2012).The age-adjusted rate (AAR) of gastric cancer among urban registries in India is (3.0-13.2) compared to the worldwide AAR (4.1-95.5) with China having the highest incidence of AAR. Amongst all the population based cancer registries in India, Papumpure district (Arunachal Abstract Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicated in advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2 positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-East India and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of 68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examination from September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational (epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved, standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters. Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantly higher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patients with well differentiated histology and was more common in patients with stage II and III diseases, but neither of the associations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours (56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patients with locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlated significantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expression is recommended to provide a therapeutic advantage in Indian patients.

show abstract

“…HER2 positivity was defined as IHC 3+ or IHC 2+ plus SISH+. Regarding the primary study objective, the HER2-positive rate was 10.8% based on data from 14 local laboratories, and slightly lower than the rates reported by other studies [91011]. Moreover, this rate was much lower than the rate reported by the ToGA trial (IHC 3+ or IHC 2+/FISH+; 16.0%) [5].…”

Section: Discussionmentioning

confidence: 82%

Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

PurposeThe Trastuzumab for gastric cancer (GC) trial identified human epidermal growth factor receptor 2 (HER2) as a predictor of successful treatment with trastuzumab (HER2 receptor targeting agent) among patients with advanced/metastatic GC. To date, the prevalence of HER2 overexpression in the Korean population is unknown. The present study aimed to assess the incidence of HER2 positivity among GC and gastroesophageal (GE) junction cancer samples and the relationship between HER2 overexpression and clinicopathological characteristics in Korean patients.Materials and MethodsTumor samples collected from 1,695 patients with histologically proven GC or GE junction enrolled at 14 different hospitals in Korea were examined. After gathering clinicopathological data of all patients, HER2 status was assessed by immunohistochemistry (IHC) at each hospital, and IHC 2+ cases were subjected to silver-enhanced in situ hybridization at 3 central laboratories.ResultsA total of 182 specimens tested positive for HER2, whereas 1,505 tested negative. Therefore, the overall HER2-positive rate in this study was 10.8% (95% confidence interval=9.3%–12.3%). The HER2-positive rate was higher among intestinal-type cases (17.6%) than among other types, and was higher among patients older than 70 years and 50 years of age, compared to other age groups.ConclusionsOur evaluation of the HER2 positivity rate (10.8%) among Korean patients with GC and GE junction indicated the necessity of epidemiological data when conducting studies related to HER2 expression in GC and GE junction.

show abstract

Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection

Cited by 21 publications

References 22 publications

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study

Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population

Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer

Contact Info

Product

Resources

About